Altogether, the data demonstrate that in response to the cytotoxic effects of doxorubicin, tumor cells trigger activation of a key prosurvival AKT pathway to phosphorylate IGPR-1 at Ser220, which in part significantly contributes to decreased sensitivity of tumor cells to the cytotoxic effects of doxorubicin. This evidence concerns the gene AKT1 and neoplasm.